论文部分内容阅读
目的观察左卡尼汀对肾衰血液透析患者贫血的治疗效果。方法选择慢性肾衰维持性血液透析病患者54例,随机分为治疗组和对照组各27例。二组均血液透析2～3次/周,每次4h,同时给予促红细胞生成素50～75IU/(kg.次),每周2次,皮下注射。治疗组于每次血液透析结束后在促红细胞生成素治疗基础上加用左卡尼汀,将左卡尼汀1g溶于生理盐水静注。二组疗程均为12周。结果治疗组Hb、HCT水平与治疗前相比明显上升(P<0.01),且明显高于对照组(P<0.05),不良反应发生率、促红细胞生成素用量与对照组相比明显减少。结论在常规治疗的基础上加用左卡尼汀治疗肾衰血液透析患者贫血,可以在临床上推广应用。
Objective To observe the therapeutic effect of levocarnitine on anemia in hemodialysis patients with renal failure. Methods 54 patients with chronic renal failure hemodialysis patients were randomly divided into treatment group and control group of 27 cases. Two groups were hemodialysis 2 to 3 times / week, each time 4h, given erythropoietin 50 ~ 75IU / (kg. Times), twice a week, subcutaneous injection. In the treatment group, levocarnitine was added on the basis of erythropoietin treatment after each hemodialysis, and 1 g of levocarnitine was dissolved in saline intravenously. The two groups were treated for 12 weeks. Results The levels of Hb and HCT in treatment group were significantly higher than those before treatment (P <0.01), and were significantly higher than those in control group (P <0.05). The incidence of adverse reactions and erythropoietin consumption were significantly lower than those in control group. Conclusion The addition of levocarnitine on the basis of routine treatment of hemodialysis patients with renal failure anemia, which can be widely used in clinical practice.